Dr. James Tobin

Jim is the Vice President of Cardiovascular & Metabolic Scientific Innovation at the Johnson & Johnson Innovation, Boston.  He has over 23 years of drug development experience in the areas of hemostasis, inflammation, muscle degenerative diseases, and diabetes.  Most recently, Jim was an entrepreneur-in-residence at Atlas Venture and focused on company formation in the life science sector.

Prior to joining Atlas, Jim held the position of Vice President and Chief Scientific Officer at Pfizer leading a research unit focused on the development of biologics for the treatment of metabolic diseases and hemophilia.  Prior to that he held the role of Vice President of Cardiovascular and Metabolic Diseases at Wyeth Pharmaceuticals and led the metabolic disease group with a focus on both small molecule and protein therapeutics in type 2 diabetes and muscle disease.  Under Jim’s direction these groups advanced over 15 biologics and small molecules into clinical development.

Jim began his career at Genetics Institute (GI) where he was part of the structure based drug discovery group and was involved in the research and development of a number of biopharmaceutical products in inflammation, transplantation and thrombocytopenia, including the marketed product Neumega.

Jim obtained his PhD in Biochemistry from Brandeis University and completed his NRSA postdoctoral fellowship at Harvard University.  He has authored 50 publications in peer-reviewed journals and is the inventor on 10 patents.